Fmr LLC Purchases 685,623 Shares of Allakos Inc. (NASDAQ:ALLK)

Fmr LLC raised its position in shares of Allakos Inc. (NASDAQ:ALLK) by 14.6% in the third quarter, HoldingsChannel reports. The firm owned 5,370,247 shares of the company’s stock after acquiring an additional 685,623 shares during the period. Fmr LLC owned about 0.06% of Allakos worth $3,508,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ALLK. Point72 DIFC Ltd bought a new position in shares of Allakos in the 2nd quarter worth $25,000. Cubist Systematic Strategies LLC bought a new position in shares of Allakos in the 2nd quarter worth $55,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Allakos in the 2nd quarter worth $112,000. GSA Capital Partners LLP raised its position in shares of Allakos by 11.9% in the 3rd quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock worth $519,000 after acquiring an additional 84,750 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of Allakos by 32.4% in the 2nd quarter. Acadian Asset Management LLC now owns 1,762,814 shares of the company’s stock worth $1,761,000 after acquiring an additional 431,175 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

Allakos Price Performance

Shares of ALLK stock opened at $1.05 on Friday. Allakos Inc. has a 1-year low of $0.54 and a 1-year high of $3.41. The stock’s fifty day moving average price is $1.05 and its 200 day moving average price is $0.91. The company has a market cap of $93.81 million, a price-to-earnings ratio of -0.52 and a beta of 0.92.

Allakos (NASDAQ:ALLK) last announced its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. As a group, equities research analysts anticipate that Allakos Inc. will post -1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, JMP Securities reissued a “market outperform” rating and issued a $3.00 price target on shares of Allakos in a research report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $1.67.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.